| Octreotid-Mepha LA 20 mg, Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension - | | 67154002 | | Mepha Pharma AG | | Octreotid-Mepha LA 20 mg, Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension | | 19.07.2019 | | | | | 19.07.2019 | | Octreotid (H01CB02) | | | | DDD-OMS | | | | 07.16.20. | | | | 07.16.20. | | | | | | | | Non | | | | IPro | | | | | | | | N.O. | | | | FB | | | | 7680671540024 | | Synthetika | | | | |
| | Composition | | Praeparatio sicca: octreotidum 20 mg ut octreotidi acetas, poly(lactidum-co-glycolidum), mannitolum, pro vitro.
Solvens: carmellosum natricum corresp. natrium 1.512 mg, mannitolum, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 2 ml. | | Packungsbestandteile | | Lyophilisat et solvant | | | | | | | | Principe actif | Concentr. | informations additionels |
|---|
| Octreotide | 20 mg | Praeparatio sicca |
| | BAG: Principe actif | Concentr. |
|---|
| Octreotide | 20 mg |
| | | | Agents auxilliaires |
|---|
| Mannitol | | Poly(Lactidum-Co-Glycolidum) |
| |
| Solvens | | | Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension | | | | | | | | | BAG: Principe actif | Concentr. |
|---|
| Octreotide | 20 mg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Carmellose Sodique | | | Mannitol | | | Poloxamer | 188 |
| |
| | Source | | | |
|
|
